Pay in 4 interest-free payments of $5.16 Learn more
Ships within 48 hours · Estimated delivery Sep 6 - Sep 11
In clinical trials, patients on semaglutide 2.4 mg lost an average of about 15% of their body weight over 68 weeks
Currently a research peptide, it is hoped in the future it could offer a therapeutic treatment for the following: Hypoactive Sexual Desire Disorder PT-141 peptide stimulates sexual desire and arousal in individuals with hypoactive sexual desire disorder (HSDD) through its unique mechanism of action
This medication can also be beneficial for individuals with specific underlying medical conditions contributing to weight gain, such as Cushings syndrome, hypothyroidism, or certain genetic disorders
Drugs 71, 16751688
Pure composition no unnecessary excipients, high bioavailability, and safe to use
Easy measuring 10 units on a U-100 insulin syringe = 0.10 mL = about 2.33 mg total blend
US$ 21.74
US$ 20.60
US$ 22.39
US$ 23.66
